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COVID-19 vaccination of children has begun in various high-income 
countries with regulatory approval and general public support, but 
largely without careful ethical consideration. This trend is expected to 
extend to other COVID-19 vaccines and lower ages as clinical trials 
progress. This paper provides an ethical analysis of COVID-19 
vaccination of healthy children. Specifically, we argue that it is 
currently unclear whether routine COVID-19 vaccination of healthy 
children is ethically justified in most contexts, given the minimal direct 
benefit that COVID-19 vaccination provides to children, the potential 
for rare risks to outweigh these benefits and undermine vaccine 
confidence, and substantial evidence that COVID-19 vaccination 
confers adequate protection to risk groups, such as older adults, 
without the need to vaccinate healthy children. We conclude that child 
COVID-19 vaccination in wealthy communities before adults in poor 
communities worldwide is ethically unacceptable and consider how 
policy deliberations might evolve in light of future developments.
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          Amendments from Version 1
We are grateful to the reviewers that have given us valuable 
feedback on the first version of our open letter. We have edited 
this piece accordingly. We have made the ethical framework 
of analysis more explicit, both in the introduction and in 
the last paragraph of the open letter. We also refer to the 
relevant public health ethics literature for several more specific 
arguments (e.g., in the “Protecting risk groups does not require 
vaccinating children” section). We also grapple with a common 
the individual risk/benefit calculus for COVID-19 vaccination: 
even if there is some risk to children, the benefit of decreased 
onward transmission is worth it--i.e., that children potentially 
assume risk for population-level benefits. We specify that our 
analysis is targeted for young, healthy children (e.g., those aged 
under 15 with no comorbidities), acknowledging that relevant 
considerations may change in older children or those with 
significant medical conditions. We also added in discussion 
regarding the threat of multisystem inflammatory syndrome 
(MIS-C) death resulting from COVID-19 infection, which is an 
important consideration in weighing the costs and benefits of 
child vaccination against COVID-19. We also contextualize our 
analysis in the context of other vaccine-preventable childhood 
diseases, specifically chickenpox. Additionally, we added in 
references regarding the suspension of Moderna vaccine 
administration to younger age groups in Nordic countries. We 
also grapple with the risk that COVID-19 vaccination could pose 





The views expressed in this article are those of the author(s). 
Publication in Wellcome Open Research does not imply 
endorsement by Wellcome.
Introduction
There has been relatively little ethical analysis of vaccinat-
ing children against COVID-19. While the approval of a 
COVID-19 vaccine for children is a testament to rapid scien-
tific progress during the pandemic, applications of scientific 
achievements are not by default ethically sound1. In this piece, 
we explore the ethics of vaccinating children against COVID-19 
from a global public health ethics perspective, given the: mini-
mal direct benefit for young healthy children, the potential for 
rare risks to outweigh such benefits or undermine vaccine confi-
dence, and increasing evidence that COVID-19 vaccination of 
risk groups such as older adults adequately protects these groups 
without the need to vaccinate children. We expand our analy-
sis to the global level, highlighting international inequities of 
COVID-19 vaccine availability and burden of disease. Finally, 
we discuss potential scenarios in which there could be a 
stronger ethical case in favor of vaccinating children against 
COVID-19. We conclude that it is currently difficult to ethically 
justify the routine vaccination of healthy children, especially 
given inequitable global vaccine availability.
Minimal benefit to healthy children
Our ethical analysis is focused on young healthy children 
(e.g., those aged under 15 with no comorbidities), acknowledging 
that relevant considerations may change in older children or 
those with significant medical conditions. Overall, the risks of 
severe illness are markedly lower in young children than in 
older adults, and children are also less susceptible than adults to 
becoming infected with the virus2,3. The emergence of the Delta 
COVID-19 variant has led some commentators to argue that 
child COVID-19 vaccination is justified by relevant differences 
between this and previous variants4. We challenge this claim, 
for there is currently “no clear evidence that children are more 
vulnerable to or more affected by Delta compared with earlier 
variants”5. The burden of COVID-19 in children is similar 
to or lower than that of typical seasonal influenza during the 
winter6. Nevertheless, the rare cases of children hospitalized 
with COVID-19 may be severe, and children with certain comor-
bidities may be at higher risk6. It may well be justifiable to 
trial and eventually use vaccines routinely in children with cer-
tain comorbidities, but it is much harder to justify the vacci-
nation of healthy children on the basis of expected benefits to 
them, given the extremely mild average disease severity. Further, 
post-infection immunity is at least as effective as vaccination 
at protecting against (re-)infection in later life, which might 
otherwise have been more severe7,8.
With this in mind, healthy children can suffer significant adverse 
effects from COVID-19, but these outcomes are rare. The dis-
ease rarely causes severe inflammatory states9 and death in 
healthy children, and such outcomes are more common among 
children with significant comorbidities10. Every child death is 
a tragedy. Still, current data suggests these cases to be a small 
minority of COVID-19 cases among healthy children. It is some-
times claimed that even healthy children frequently experience 
significant post-acute symptoms (‘long covid’) after mild or 
asymptomatic infection. However, careful analyses of available 
data have shown this to be unsupported by current evidence11–13. 
Though some COVID illness duration in children is prolonged, 
research suggests that the burden of symptoms does not increase 
with time14. Likewise, post-COVID-19 fatigue is strongly cor-
related with the severity of the acute illness in adults15. Since 
COVID-19 is generally mild or asymptomatic in healthy 
children, it is implausible that post-acute symptoms would fre-
quently be severe. Thus, protecting healthy children against long 
covid does not in itself provide sufficient justification for routine 
COVID-19 vaccination of healthy children.
Ultimately, unlike many other vaccine-preventable diseases, 
healthy children are at low risk of COVID-19 morbidity, and 
mortality16. As long as COVID-19 cases remain on average mild or 
asymptomatic in children, very large numbers of children would 
need to be vaccinated to prevent one pediatric COVID-19 hos-
pital admission17. In our view, routine or mandated COVID-19 
vaccination of healthy children cannot be justified on the basis 
of direct individual benefits, and any small, expected benefit 
may be outweighed by risks and uncertainties.
Potential risks in children
Policymakers should be especially cautious about potential 
risks of COVID-19 vaccines in children. First, because avoid-
ing harm to healthy children is arguably key to maintaining vac-
cine confidence18. Second, because there are risks associated 
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with, for example, current mRNA and viral vector vaccines19. 
Since the expected benefits of COVID-19 vaccination in 
children are low, even rare harms are highly salient to the ethi-
cal acceptability of routine healthy child vaccination with any 
COVID-19 vaccine. Initial safety data from the clinical trials that 
motivated the EUA authorization of the Pfizer-BioNTech vac-
cine for children included 2,260 participants aged 12 to 15, of 
which 1,131 received the vaccine, and the remainder (1,129) 
received a placebo20. Recent data suggest that myocarditis is an 
important rare harm associated with mRNA vaccination, affect-
ing primarily adolescents and young adults, more commonly 
occurring after the second dose of vaccine, and with a rate in 
males approximately 10 times that in females21.
Although long-term harms related to vaccines are rare, there 
should ideally be prolonged follow-up of pediatric trial partici-
pants before routine COVID-19 childhood vaccination, especially 
given the minimal expected direct benefits vaccination would 
provide for children22. Traditionally, childhood vaccines are 
developed over decades, with clinical trial safety testing con-
tinuing for years, as was the case for the chickenpox vaccine23. 
Pfizer released the topline adolescent (12–15 years old) data24, 
which might at least rule out common adverse events occur-
ring less than eight months post-vaccination. Still, more data are 
needed. Since relatively few children were involved in the Pfizer-
BioNTech clinical trials, and follow-up has not yet been of long 
duration, regulators are arguably poorly placed to evaluate the 
risks of rare or delayed adverse outcomes25. Sweden, Norway, and 
Finland have suspended use of the Moderna COVID-19 vaccine 
in young people “as a precaution” following the increased detec-
tion of adverse side effects such as myocarditis and pericarditis26. 
Initial data on the long-term outcomes of mRNA-vaccine asso-
ciated myocarditis, for example, are due to be published in 
late 202121. Moreover, COVID-19 is not a pediatric public 
health emergency25. As a result, we agree with other authors 
who have suggested that standard criteria for EUA authorization 
of the Pfizer-BioNTech COVID-19 vaccine for use in children 
have not been met25.
Historically, vaccine-related harms to children and overly hasty 
pediatric vaccine rollouts have undermined public confidence 
in vaccines and cost lives. For example, by the time the risks 
of a licensed dengue vaccine to a minority of children were 
confirmed, the Philippines had already vaccinated 830,000 chil-
dren, many of whom faced increased disease risks if they had 
never been infected with dengue before27. As a result, at least 130 
children died28. Public trust in other vaccines collapsed, lead-
ing to local outbreaks of measles and increased risks of other 
vaccine-preventable diseases18,29.
Moreover, after the 2009 influenza pandemic, children were 
identified to be at a greater risk of narcolepsy as a rare vac-
cine-related harm (five-to-fourteen-fold increase in children as 
opposed to a two-to-seven-fold increase in adults)30. As a 
result, some public health authorities suspended the use of this 
vaccine in children amid public controversy31.
Defects in vaccine production can also pose unintended nega-
tive adverse effects in children. Historically, production defects 
with polio vaccines, for example, were associated with at 
least one high profile case of harmful outcomes in children, 
which undermined vaccine confidence at the time32. While the 
Pfizer-BioNTech vaccine is not a live-attenuated virus, defec-
tive production has already occurred for COVID-19 vaccines 
(e.g., ingredient conflation in 15 million doses of the John-
son & Johnson vaccine)33. Were such defects to go undetected, 
they might pose harm to vaccine recipients, which, for the rea-
sons outlined above, would be especially concerning in pediatric 
populations34.
Public trust in vaccines, particularly child vaccines, takes years 
to build and days to break. Rare or long-term vaccine-induced 
risks in children, whether due to defective production or intrin-
sic to the vaccine but not detected in prior studies, have thus 
undermined public confidence in the associated vaccines and 
vaccines in general18,35,36. This remained true even when the 
harms were very rare and if there was an ex-ante net benefit in 
children. Since it is currently unclear whether mRNA vac-
cines for COVID-19 are associated with a net benefit in young 
healthy children, vaccine policy should proceed with caution37. 
This is especially true for healthy children who have post-infec-
tion immunity to COVID-19, in whom the benefits of vaccination 
are likely even smaller and the risks even more uncertain due to 
lack of data in this group, who (despite this) may receive vaccines 
as part of routine or mandated policies.
Rather than hastily expanding the use of COVID-19 vaccines in 
children, a more responsible approach would be to prioritize 
the systematic collection of pediatric safety and effectiveness 
data, ideally in placebo-controlled studies. Such studies remain 
ethical, including from the point of view of equipoise, since 
it is currently a matter of debate whether the benefits of mRNA 
vaccines outweigh the risks in healthy children. Such studies 
could be simultaneous with expansion of access for adolescents 
with comorbidities in whom the individual benefits more plausi-
bly outweigh risks. If the risks or uncertainties related to mRNA 
vaccine use in children using standard schedules turn out to 
be unacceptably high, policymakers could also consider test-
ing single mRNA dose regimens (given that risk of myocardi-
tis appears to increase significantly with the second dose) and/or 
more widespread use of other types of vaccines (e.g., whole 
inactivated virus vaccines), which may have a more acceptable 
safety profile in children38.
Protecting risk groups does not require 
vaccinating children
Child vaccination is often partly justified by the need to prevent 
the spread of infections from healthy children to others, includ-
ing (non-pediatric) risk groups39,40. Some may argue that the 
risk posed to healthy children by COVID-19 vaccination may 
be justified by the benefit of decreased onward transmission, 
at least if this benefit proves to be significant and sustainable 
over the long term with current vaccines. We reject this claim. 
Older adults and other COVID-19 risk groups can be protected 
without vaccinating children for at least two reasons. First, 
because children are responsible for a relatively small frac-
tion of transmission outside of households. Second, because 
COVID-19 vaccines are highly effective against severe disease 
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even where vaccinated individuals are exposed to infection, 
whether by children or adults.
Data suggest that children are less susceptible to developing 
SARS-CoV-2 infection and, even if infected, are less likely to 
infect others as compared to adults41. The majority of secondary 
infections directly attributable to children occur within house-
holds. If adult household members are vaccinated, the risks to 
the wider community may be reduced still further42,43. Though 
controversy persists regarding the effect of school closures on 
COVID-19 community transmission, recent data suggest that 
reopening schools does not result in large resurgent epidem-
ics of severe disease in populations where a large proportion of 
adults are vaccinated43,44. In sum, children are not major vectors 
of COVID-19 transmission, insofar as their risks of becoming 
infected are lowered further by high rates of adult vaccination.
Perhaps the strongest case against child COVID-19 vaccina-
tion is the fact that COVID-19 vaccines are safe and effec-
tive in higher-risk groups, including older adults and the 
immunocompromised22,45. Ethical arguments in favor of vac-
cinating healthy, young people for the benefit of others in the 
context of other diseases generally emphasize that the genera-
tion of population (“herd”) immunity is one of the only ways to 
protect vulnerable risk groups46. Such risk groups may be 
unable to generate a sufficient immune response to other vac-
cines, such as those for influenza and pneumococcus47–49. In 
these cases, risk groups might depend on healthy children to get 
vaccinated in order to protect others. This is not the case for 
COVID-19. Risk groups experience highly effective protec-
tion against severe COVID-19 from currently available vaccines, 
even if they are exposed to significant community transmission50. 
As a result, the ethical claim that young, healthy children 
should get vaccinated especially for the benefit of risk groups 
– which might constitute a strong argument in favor of the vac-
cination of healthy children against other diseases – does not 
hold in the case of COVID-19 vaccines1,51.
Overall, the contribution to population-level immunity per 
child vaccinated is significantly lower than the contribution per 
adult vaccinated. Inadequate vaccination of adult populations 
should not be an excuse for the vaccination of children. Fur-
thermore, it would be poorly cost-effective and ethically unjus-
tified to use children as a means to protect vaccine-hesitant 
adults – especially if vaccinating children involves non-trivial 
risks.
Once a high proportion of adults are vaccinated, if residual 
transmission levels and disease burden are deemed unaccept-
able, COVID-19 vaccination of children might, under certain 
conditions, produce additional reduction in these outcomes. Such 
conditions may include higher risk individuals who happen to 
be poorly protected by vaccines remaining at risk by exposure 
to otherwise-healthy children infected with COVID-19. Until 
adult vaccination uptake in communities is maximized, it 
is not clear that it would be ethically justifiable to promote 
COVID-19 vaccination of children to boost population immu-
nity. Moreover, since current COVID-19 vaccines do not provide 
sterilizing immunity, and since post-vaccination infections are 
relatively common, no amount of community vaccination will 
produce elimination of transmission. Vaccinated adults will be 
infected sooner or later. While higher rates of child vaccina-
tion might delay infections in some adults to some degree, these 
infections cannot be prevented. The ubiquity of post-vaccination 
infections and re-infections therefore undermines the weight 
of any ethical argument to the effect that vaccinating children 
is required to prevent harm to others.
Perpetuation of global vaccine inequities
The COVID-19 pandemic has been characterized by domes-
tic and international inequities52, including but not limited to 
inequities in the distribution of the burdens of disease, scarce 
healthcare resources, social and economic opportunities, and, 
most recently, vaccines53. As of April 2021, 700 million COVID-
19 vaccine doses had been globally administered, with high 
income countries (HICs) securing 87% of doses, and low-income 
countries (LICs) securing only 0.2% of doses54. These inequities 
are further exacerbated by the administration of ‘booster’ vac-
cines in HICs, while LMICs remain without first and second 
doses. Israel now administers ‘booster’ doses to all eligible indi-
viduals five months after their second dose55, while Germany, 
France, and the United States anticipate boosting all eligible 
individuals from September 202156,57. Though many HICs have 
committed to donate COVID-19 vaccine doses to low- and 
middle-income countries (LMICs), these donations are only 
a small fraction of the 1.8 billion dose goal of COVAX and are 
not a sustainable solution to equitably vaccinating higher risk 
individuals worldwide58.
Vaccinating adults in LMICs alongside those in HICs is argu-
ably the best way of ensuring global equity and ensuring posi-
tive child health and wellbeing outcomes59. Adults are often 
the key support for one or more children and other vulnerable 
populations, such as older adults60. When that support sys-
tem is threatened, either through illness or death, children suf-
fer socially and economically. As a result, children may have 
to stop attending school, or other social services, in order to 
work – or may be forced into child marriages, which have 
increased in frequency during the pandemic61. Accordingly, the 
social benefit of vaccinating adults, particularly in LMICs, far 
outweighs the benefit of vaccinating healthy children in HICs51. 
As a global community, we should focus on vaccinating adults in 
LMICs – beginning with healthcare workers and older adults 




Ethical evaluations of routine childhood vaccination against 
COVID-19 are, of course, subject to future developments. 
First, international travel has not returned to pre-pandemic 
levels (and many countries’ borders have been closed or entry 
restricted)62. An increase in travel might increase transmis-
sion – though not necessarily affecting disease burden to the 
same degree, provided that vaccines and post-infection immu-
nity remain effective in the prevention of severe disease. 
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Second, the UK and Israel have a high level of population 
immunity due to past infection, whereas countries that largely 
eliminated COVID-19 (for example Australia, New Zealand, or 
Taiwan63) might require even higher rates of adult vaccination to 
achieve similar levels of disease control. Third, vaccine-derived 
immunity may wane over time, especially where individuals 
are not re-exposed to infection soon after vaccination.
As a result, one might think that there would be contexts in 
which child COVID-19 vaccination would be more ethically 
acceptable on a routine basis than is currently the case. How-
ever, some factors leading to unacceptable disease burdens 
could be mitigated with other measures. For example, waning 
immunity could be controlled by repeat ‘booster’ COVID-19 vac-
cination of vulnerable adults64. Moreover, since SARS-CoV-2 
will likely become globally endemic65, causing mild childhood 
illness akin to other seasonal human coronaviruses, post-infec-
tion immunity in children will also make a positive contribution 
to disease control. The case for vaccinating children might there-
fore become even weaker in the long term since post-infec-
tion immunity will be well-matched to circulating variants and 
robust across closely related variants as is known to be the case 
for other coronaviruses8,66. Post-infection immunity in chil-
dren might thus be expected to provide more sustainable public 
health benefits than a reliance on regular updates of vaccines.
Furthermore, there is increasing evidence that COVID-19 vac-
cines do not altogether prevent infection67. This creates a con-
cern that by vaccinating children, infection may only be delayed 
(through waning vaccine efficacy), thus instigating the poten-
tial need for ‘booster’ shots. While the risk-benefit profile of 
offering ‘boosters’ to groups at high risk may turn out to be 
favorable, this is unlikely to be the case for children, given the 
previously discussed low net benefits of COVID-19 vaccination 
and the potential for any harms to outweigh those benefits.
Despite some public health officials suggesting otherwise, and 
even going so far as to advocate for mandatory child COVID-19 
vaccination68, the Delta variant currently does not threaten the 
feasibility of high adult COVID-19 vaccination uptake to control 
disease burden. As a result, the ethical acceptability of routine 
COVID-19 vaccination of healthy children is currently weak 
– and the case for mandating even weaker. Nevertheless, should 
high adult vaccination uptake be insufficient to control dis-
ease burden – as opposed to mere transmission of the virus – a 
stronger case for routine child COVID-19 vaccination could 
emerge. Even then, however, there may still be ethical reasons to 
target adult populations before children69. Additionally, the ethi-
cal acceptability of routine child COVID-19 vaccination under any 
circumstances is contingent on reliable long-term safety data 
from clinical trials involving children. Should severe side effects 
arise in healthy children, even if they are rare, the overall pub-
lic health harms of vaccinating healthy children, including 
reductions in vaccine confidence, may outweigh any benefits.
Ultimately, parents and guardians of children should weigh the 
potential risks and benefits of vaccination in their own con-
text. Currently, every vaccine used for a healthy child in a 
wealthy community would most likely be better used for an adult 
at high risk of severe illness from COVID-19 in a poor commu-
nity. Perhaps in the future, should global vaccine supply be suf-
ficient to meet demand, and should more data become avail-
able regarding the long-term safety of COVID-19 vaccines in 
children, ethical considerations might weigh in favor of 
COVID-19 vaccination of children, without making COVID-19 
vaccines routine or mandatory for all children. At present, espe-
cially from a global public health ethics perspective, routine 
vaccination of healthy children against COVID-19 on balance, 
to be unjustified.
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References
1.  Savulescu J, Giubilini A, Danchin M: Global Ethical Considerations Regarding 
Mandatory Vaccination in Children. J Pediatr. 2021; 231: 10–6.  
PubMed Abstract | Publisher Full Text | Free Full Text 
2.  Verity R, Okell LC, Dorigatti I, et al.: Estimates of the severity of coronavirus 
disease 2019: a model-based analysis. Lancet Infect Dis. 2020; 20(6): 669–77. 
PubMed Abstract | Publisher Full Text | Free Full Text 
3.  Salje H, Tran Kiem C, Lefrancq N, et al.: Estimating the burden of SARS-CoV-2 
in France. Science. 2020; 369(6500): 208–11.  
PubMed Abstract | Publisher Full Text | Free Full Text 
4.  Roifman CM, Vong L: Children should be offered vaccination against COVID-
19. LymphoSign Journal. 2021.  
Reference Source
5.  Mallapaty S: Kids and COVID: why young immune systems are still on top. 
Nature. 2021; 597(7875): 166–8.  
PubMed Abstract | Publisher Full Text 
6.  Piroth L, Cottenet J, Mariet AS, et al.: Comparison of the characteristics, 
morbidity, and mortality of COVID-19 and seasonal influenza: a 
nationwide, population-based retrospective cohort study. Lancet Respir Med. 
2021; 9(3): 251–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
7.  Pritchard E, Matthews PC, Stoesser N, et al.: Impact of vaccination on SARS-
CoV-2 cases in the community: a population-based study using the UK’s 
COVID-19 Infection Survey. medRxiv. 2021.  
Publisher Full Text 
8.  Wadman M: Having SARS-CoV-2 once confers much greater immunity than 
a vaccine—but vaccination remains vital. Science. 2021; updated August 26, 
2021.  
Publisher Full Text 
9.  Blumfield E, Levin TL, Kurian J, et al.: Imaging Findings in Multisystem 
Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus 
Disease COVID-19. [published online ahead of print on July 29, 2020] AJR Am J 
Roentgenol. 2021; 216(2): 507–517.  
PubMed Abstract | Publisher Full Text 
10.  Ward JL, Harwood R, Smith C, et al.: Risk factors for intensive care admission 
and death amongst children and young people admitted to hospital with 
COVID-19 and PIMS-TS in England during the first pandemic year. medRxiv. 
2021.  
Publisher Full Text 
11.  Bhopal SS, Absoud M: Vaccinating children to prevent long covid? More 
caution is needed in interpreting current epidemiological data. BMJ. 2021; 
Page 6 of 13
Wellcome Open Research 2021, 6:252 Last updated: 29 NOV 2021
372: n520.  
PubMed Abstract | Publisher Full Text 
12.  Hertting O: More research is needed on the long-term effects of COVID-19 
on children and adolescents. Acta Paediatr. 2021; 110(3): 744–5.  
PubMed Abstract | Publisher Full Text | Free Full Text 
13.  Ayoubkhani D, Pawelek P, Gaughan C: Technical article: Updated estimates 
of the prevalence of post-acute symptoms among people with coronavirus 
(COVID-19) in the UK: 26 April 2020 to 1 August 2021. Office for National 
Statistics; Released 16 September, 2021. Accessed 18 November, 2021. 2021.  
Reference Source
14.  Molteni E, Sudre CH, Canas LS, et al.: Illness duration and symptom profile in 
symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child 
Adolesc Health. 2021; 5(10): 708–718.  
PubMed Abstract | Publisher Full Text 
15.  Crameri GAG, Bielecki M, Zust R, et al.: Reduced maximal aerobic capacity 
after COVID-19 in young adult recruits, Switzerland, May 2020. Euro Surveill. 
2020; 25(36): 2001542.  
PubMed Abstract | Publisher Full Text | Free Full Text 
16.  Bhopal SS, Bagaria J, Olabi B, et al.: Children and young people remain at 
low risk of COVID-19 mortality. Lancet Child Adolesc Health. 2021; 5(5): e12–e3. 
PubMed Abstract | Publisher Full Text | Free Full Text 
17.  Lavine JS, Bjornstad O, Antia R: Vaccinating children against SARS-CoV-2. BMJ. 
2021; 373: n1197.  
PubMed Abstract | Publisher Full Text 
18.  Larson HJ, Hartigan-Go K, de Figueiredo A: Vaccine confidence plummets 
in the Philippines following dengue vaccine scare: why it matters to 
pandemic preparedness. Hum Vaccin Immunother. 2019; 15(3): 625–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
19.  WHO: The Oxford/AstraZeneca COVID-19 vaccine: what you need to know. 
2021; [updated September 2, 2021].  
Reference Source
20.  Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 
Vaccine for Emergency Use in Adolescents in Another Important Action in 
Fight Against Pandemic. [press release]. 2021.  
Reference Source
21.  Su JR: Myopericarditis following COVID-19 vaccination: Updates from the 
Vaccine Adverse Event Reporting System (VAERS). CDC Awardee COVID-19 
Vaccination Planning Meeting; 2021.  
Reference Source
22.  Eberhardt CS, Siegrist CA: Is there a role for childhood vaccination against 
COVID-19? Pediatr Allergy Immunol. 2021; 32(1): 9–16.  
PubMed Abstract | Publisher Full Text 
23.  Altman Lawrence K: After Long Debate, Vaccine For Chicken Pox Is 
Approved. The New York Times. 1995.  
Reference Source
24.  Pfizer: ABOUT OUR LANDMARK TRIAL. 2021.  
Reference Source
25.  Pegden W, Prasad V, Baral S: Covid vaccines for children should not get 
emergency use authorization. The BMJ Opinion. 2021.  
Reference Source
26.  Paterlini M: Covid-19: Sweden, Norway, and Finland suspend use of 
Moderna vaccine in young people “as a precaution”. BMJ. 2021; 375: n2477. 
PubMed Abstract | Publisher Full Text 
27.  Normile D: Safety concerns derail dengue vaccination program. Science. 
2017; 358(6370): 1514–5.  
PubMed Abstract | Publisher Full Text 
28.  Arkin F: Dengue vaccine fiasco leads to criminal charges for researcher in 
the Philippines. Science. 2019.  
Publisher Full Text 
29.  Migriño J Jr, Gayados B, Birol KRJ, et al.: Factors affecting vaccine hesitancy 
among families with children 2 years old and younger in two urban 
communities in Manila, Philippines. Western Pac Surveill Response J. 2020; 
11(2): 20–6.  
PubMed Abstract | Publisher Full Text | Free Full Text 
30.  Sarkanen TO, Alakuijala APE, Dauvilliers YA, et al.: Incidence of narcolepsy 
after H1N1 influenza and vaccinations: Systematic review and meta-
analysis. Sleep Med Rev. 2018; 38: 177–86.  
PubMed Abstract | Publisher Full Text 
31.  Collignon P, Doshi P, Jefferson T: Child influenza vaccination. Ramifications 
of adverse events in children in Australia. BMJ. 2010; 340: c2994.  
PubMed Abstract | Publisher Full Text 
32.  Fitzpatrick M, Weiland N: The Cutter Incident: How America’s First Polio 
Vaccine Led to a Growing Vaccine Crisis. J R Soc Med. 2006; 99(3): 156. 
Publisher Full Text | Free Full Text 
33.  LaFraniere S, Weiland N: Factory Mix-Up Ruins Up to 15 Million Vaccine 
Doses From Johnson & Johnson. The New York Times. 2021.  
Reference Source
34.  Swift R: Japan’s Moderna vaccine contamination woes widen as regions put 
holds on shots. Reuters. 2021.  
Reference Source
35.  Lundgren B: ‘Rhyme or reason?’ Saying no to mass vaccination: subjective 
re-interpretation in the context of the A(H1N1) influenza pandemic in 
Sweden 2009-2010. Med Humanit. 2015; 41(2): 107–12.  
PubMed Abstract | Publisher Full Text | Free Full Text 
36.  Oikkonen V: The 2009 H1N1 pandemic, vaccine-associated narcolepsy, and 
the politics of risk and harm. Health (London). 2020; 1363459320925880. 
PubMed Abstract | Publisher Full Text 
37.  ( JCVI) JCoVaI: JCVI statement on COVID-19 vaccination of children aged 
12 to 15 years: 3 September 2021. Contract No.: Independent Report, 2021. 
Reference Source
38.  Wu H: China’s children may be next in line for COVID-19 vaccines. AP News; 
2021; [updated June 11, 2021].  
Reference Source
39.  Kraaijeveld SR: Vaccinating for Whom? Distinguishing between Self-
Protective, Paternalistic, Altruistic and Indirect Vaccination. Public Health 
Ethics. 2020; 13(2): 190–200.  
PubMed Abstract | Publisher Full Text | Free Full Text 
40.  Bambery B, Douglas T, Selgelid MJ, et al.: Influenza Vaccination Strategies 
Should Target Children. Public Health Ethics. 2018; 11(2): 221–34.  
PubMed Abstract | Publisher Full Text | Free Full Text 
41.  Monod M, Blenkinsop A, Xi X, et al.: Age groups that sustain resurging 
COVID-19 epidemics in the United States. Science. 2021; 371(6536): eabe8372. 
PubMed Abstract | Publisher Full Text | Free Full Text 
42.  Lei H, Xu X, Xiao S, et al.: Household transmission of COVID-19-a systematic 
review and meta-analysis. J Infect. 2020; 81(6): 979–997.  
PubMed Abstract | Publisher Full Text | Free Full Text 
43.  Judd A: COVID-19 Schools Infection Survey Round 4, England: March 2021. 
Statistical Bulletin; 2021.  
Reference Source
44.  Somekh I, Boker LK, Shohat T, et al.: Comparison of COVID-19 Incidence Rates 
Before and After School Reopening in Israel. JAMA Netw Open. 2021; 4(4): 
e217105.  
PubMed Abstract | Publisher Full Text | Free Full Text 
45.  Dagan N, Barda N, Kepten E, et al.: BNT162b2 mRNA Covid-19 Vaccine in a 
Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15): 1412–23. 
PubMed Abstract | Publisher Full Text | Free Full Text 
46.  Mastroianni AC, Kahn JP, Kass NE, et al.: Immunization and Ethics: 
Beneficence, Coercion, Public Health, and the State. The Oxford Handbook of 
Public Health Ethics. 2019; 434–47.  
Publisher Full Text 
47.  Velavan TP, Pollard AJ, Kremsner PG: Herd immunity and vaccination of 
children for COVID-19. Int J Infect Dis. 2020; 98: 14–5.  
PubMed Abstract | Publisher Full Text | Free Full Text 
48.  Plans-Rubió P: The vaccination coverage required to establish herd 
immunity against influenza viruses. Prev Med. 2012; 55(1): 72–7.  
PubMed Abstract | Publisher Full Text 
49.  Pittet LF, Posfay-Barbe KM: Pneumococcal vaccines for children: a global 
public health priority. Clin Microbiol Infect. 2012; 18 Suppl 5: 25–36.  
PubMed Abstract | Publisher Full Text 
50.  Menni C, Klaser K, May A, et al.: Vaccine side-effects and SARS-CoV-2 infection 
after vaccination in users of the COVID Symptom Study app in the UK: 
a prospective observational study. Lancet Infect Dis. 2021; 21(7): 939–949. 
PubMed Abstract | Publisher Full Text | Free Full Text 
51.  Ioannidis JPA: COVID-19 Vaccination in Children and University Students. 
Eur J Clin Invest. 2021; 51(11): e13678.  
PubMed Abstract | Publisher Full Text 
52.  Kelley M, Ferrand RA, Muraya K, et al.: An appeal for practical social justice in 
the COVID-19 global response in low-income and middle-income countries. 
Lancet Glob Health. 2020; 8(7): e888–e9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
53.  Aryeetey E, Engebretsen E, Gornitzka Å, et al.: A step backwards in the fight 
against global vaccine inequities. Lancet. 2021; 397(10268): 23–4.  
PubMed Abstract | Publisher Full Text | Free Full Text 
54.  Low-income countries have received just 0.2 per cent of all COVID-19 shots 
given. United Nations; 2021; [updated April 9, 2021].  
Reference Source
55.  Israel Expands COVID Booster Campaign to Vaccinated 12-year-olds and 
Up. Haaretz. Sect. Israel News. August 29, 2021.  
Reference Source
56.  Kar-gupta S, Copley C: Ignoring WHO call, major nations stick to vaccine 
booster plans. Reuters. Sect. World. August 5, 2021.  
Reference Source
57.  Lovelace Jr B: U.S. will begin wide distribution of Covid booster shots next 
month, saying vaccine protection wanes over time. CNBC. Sect. Health and 
Science, 2021.  
Reference Source
58.  The Editorial Board: America Is Failing Its Moral Test on Vaccines. The New 
York Times. May 14, 2021.  
Reference Source
59.  The value of COVID-19 vaccines in children: Roadmap for a safer world. 
[press release]. 2021.  
Reference Source
60.  Garfield CF, Mesman J: Time and Money: Extending Fathers’ Role in 
Economically Challenging Contexts. Pediatrics. 2016; 138(4): e20162456. 
PubMed Abstract | Publisher Full Text | Free Full Text 
61.  COVID-19: A threat to progress against child marriage. [press release]. 2021. 
Reference Source
Page 7 of 13
Wellcome Open Research 2021, 6:252 Last updated: 29 NOV 2021
62.  Health IMo: Questions and answers regarding air travel during the COVID-
19 pandemic. Gov.il. 2021. 
63.  Baker MG, Wilson N, Blakely T: Elimination could be the optimal response 
strategy for covid-19 and other emerging pandemic diseases. BMJ. 2020; 
371: m4907.  
PubMed Abstract | Publisher Full Text 
64.  Mahase E: Covid-19 booster vaccines: What we know and who’s doing what. 
BMJ. 2021; 374: n2082.  
PubMed Abstract | Publisher Full Text 
65.  Feldscher K: What will it be like when COVID-19 becomes endemic? Harvard 
T. Chan School of Public Health; 2021; [updated August 11, 2021].  
Reference Source
66.  Reed SE: The Behaviour of Recent Isolates of Human Respiratory 
Coronavirus In Vitro and in Volunteers: Evidence of Heterogeneity Among 
229E-Related Strains. J Med Virol. 1984; 13(2): 179–92.  
PubMed Abstract | Publisher Full Text | Free Full Text 
67.  Bergwerk M, Gonen T, Lustig Y, et al.: Covid-19 Breakthrough Infections in 
Vaccinated Health Care Workers. N Engl J Med. 2021; 385(16): 1474–1484. 
PubMed Abstract | Publisher Full Text | Free Full Text 
68.  So L: Fauci backs COVID-19 vaccine mandate for U.S. school children. 
Reuters. 2021; [updated August 29, 2021].  
Reference Source
69.  Giubilini A, Gupta S, Heneghan C: A focused protection vaccination strategy: 
why we should not target children with COVID-19 vaccination policies. J 
Med Ethics. 2021; 47(8): 565–566.  
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 8 of 13
Wellcome Open Research 2021, 6:252 Last updated: 29 NOV 2021
Open Peer Review
Current Peer Review Status:   
Version 1
Reviewer Report 01 November 2021
https://doi.org/10.21956/wellcomeopenres.19048.r46337
© 2021 Høeg T. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Tracy Beth Høeg   
Department of Physical Medicine & Rehabilitation, University of California-Davis, Sacramento, CA, 
USA 
This is an excellent letter. It is very important and timely. The only things I recommend the authors 
consider would be:
Making clearer what the current argument for vaccinating all children is - such as 
acknowledging there have indeed been deaths among healthy children and that MIS-C also 




It would be good to put the COVID-19 vaccine in the context of other routine childhood 
vaccinations - why they are recommended for children and how the amount of safety data 
we have on those differs from what we have the COVID-19 mRNA vaccines.  
 
2. 




Please also consider mentioning the much smaller potential benefit to children who are 
already immune and how the risk of the vaccination would most certainly outweigh the 
benefit in most of these children.
4. 
 
Thank you. I commend all of the authors on the excellent work.
 
Is the rationale for the Open Letter provided in sufficient detail?
Yes
Does the article adequately reference differing views and opinions?
Partly
Are all factual statements correct, and are statements and arguments made adequately 
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USA 
This is an excellent letter. It is very important and timely. The only things I recommend the 
authors consider would be: 
 
Making clearer what the current argument for vaccinating all children is - such as 
acknowledging there have indeed been deaths among healthy children and that MIS-C also 
poses a threat to healthy children. I think addressing these specific issues will make the 
letter stronger.
Thank you for this suggestion. We have incorporated this point into the ‘minimal 
benefit to healthy children’ section: “With this in mind, healthy children can suffer 
significant adverse effects from COVID-19. A multisystem inflammatory syndrome 
(MIS-C) has been associated with COVID-19 among healthy children, and healthy 
children have died from COVID-19. Every child death is a tragedy. Still, current data 
suggests these cases to be a small minority of COVID-19 cases among healthy 
children.” We have also added two references.
○
It would be good to put the COVID-19 vaccine in the context of other routine childhood 
vaccinations - why they are recommended for children and how the amount of safety data 
we have on those differs from what we have the COVID-19 mRNA vaccines. 
Excellent point, thank you. We have added in an example of the chickenpox vaccine in 
the ‘“potential risks to children” section.
○
Consider mentioning the suspension of Moderna in younger age groups in Nordic 
countries. 
Thank you for this suggestion! We have added this in to the “potential risks in 
children section and added the reference: Paterlini, M. (2021). Covid-19: Sweden, 
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Please also consider mentioning the much smaller potential benefit to children who are 
already immune and how the risk of the vaccination would most certainly outweigh the 
benefit in most of these children.
Thank you for suggesting incorporating this important nuance. We have included it in 
the “potential risks to children” section: “The small potential benefit to healthy 
children who have post-infection immunity to COVID-19 would most likely be 
outweighed by the potential risks of COVID-19 vaccination.”
○
Thank you. I commend all of the authors on the excellent work.
Thank you for reviewing our manuscript!○
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This article is focused on providing a synthesis of the ethics of COVID-19 vaccination for children. 
Overall, I think an evidence-based synthesis that it remains unclear even within communities to 
vaccinate all young children with the currently available vaccines and also that it is particularly 
challenging in the context of global vaccine inequities. 
 
The strengths are clear in that it takes a neutral tone and is data-driven. However, I believe it could 
be strengthened in a few ways. 
Since it is not a systematic review, I believe the way to maximize the potential impact of the work 
is to present it in the context of a broadly accepted ethical framework. It may be a single 
framework that evaluates the individual risk:benefit ratio of vaccination and then another one that 
evaluates it globally--or maybe the same framework if feasible. Either way, I think presenting it 
this way will go a long way in terms of the transition from this being a commentary to more of an 
ethical analysis. At the individual level, I also think including the argument that is often used about 
even if there is some risk to children, the benefit of decreased onward transmission is worth it--
i.e., that children potentially assume risk for population-level benefits. It would be helpful that the 
ethical analysis includes an assessment of this within broadly accepted ethical frameworks. 
 
Separately, I think the paper would do better by specifying the age of children being included in 
the analysis. Is this <18, 12-15, <12, etc as the analysis may vary based on this.
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Is the rationale for the Open Letter provided in sufficient detail?
Yes
Does the article adequately reference differing views and opinions?
Yes
Are all factual statements correct, and are statements and arguments made adequately 
supported by citations?
Partly
Is the Open Letter written in accessible language?
Yes
Where applicable, are recommendations and next steps explained clearly for others to 
follow?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Epidemiology, Clinical Medicine, HIV, Infectious Diseases
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 22 Nov 2021
Rachel Gur-Arie, Johns Hopkins University, Deering Hall, 1809 Ashland Avenue, Baltimore, 
USA 
This article is focused on providing a synthesis of the ethics of COVID-19 vaccination for 
children. 
 
Overall, I think an evidence-based synthesis that it remains unclear even within 
communities to vaccinate all young children with the currently available vaccines and also 
that it is particularly challenging in the context of global vaccine inequities. The strengths 
are clear in that it takes a neutral tone and is data-driven. However, I believe it could be 
strengthened in a few ways.
Thank you!○
Since it is not a systematic review, I believe the way to maximize the potential impact of the 
work is to present it in the context of a broadly accepted ethical framework. It may be a 
single framework that evaluates the individual risk:benefit ratio of vaccination and then 
another one that evaluates it globally--or maybe the same framework if feasible. Either way, 
I think presenting it this way will go a long way in terms of the transition from this being a 
commentary to more of an ethical analysis.
We agree with you that the best way to present our open letter is in the context of a 
broadly accepted ethical framework. The framework adopted in this open letter is the 
○
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ethics framework of global public health ethics. As bioethicists, we recognize that the 
framework in the open letter’s first version is very implicit, and we have edited 
accordingly to make our framework of analysis more explicit, both in the introduction 
and in the last paragraph of the open letter. We also refer to the relevant public 
health ethics literature for a number of more specific arguments (e.g., in the 
“Protecting risk groups does not require vaccinating children” section).
At the individual level, I also think including the argument that is often used about even if 
there is some risk to children, the benefit of decreased onward transmission is worth it--i.e., 
that children potentially assume risk for population-level benefits. It would be helpful that 
the ethical analysis includes an assessment of this within broadly accepted ethical 
frameworks.
Thank you for this suggestion, and we believe that our arguments in the “Protecting 
risk groups does not require vaccinating children” section support this claim. 
However, we have added your exact language to the beginning of the section to 
make this line of reasoning clearer.
○
Separately, I think the paper would do better by specifying the age of children being 
included in the analysis. Is this <18, 12-15, <12, etc as the analysis may vary based on this.
Thank you for this clarification. We are conducting this analysis specifically for: “young 
healthy children (e.g., those aged under 15 with no co-morbidities), acknowledging 
that relevant considerations may change in older children or those with significant 
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